IFNG and inflammatory bowel disease: Indeed, pathogenic IFNγ+ IL-17A+ cells have been identified in numerous disease settings, including multiple sclerosis (MS) and inflammatory bowel disease (IBD)7, 8, and exacerbate inflammatory disease in mouse models of these autoimmune conditions9–11.